Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"ProCare Health","sponsor":"Biovaxys","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys and Procare Health Execute US Distribution Agreement for Papilocare Gel and Oral Immunocaps","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by ProCare Health

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Papilocare (hyaluronic acid) vaginal gel is the first treatment that has been scientifically proven to have a very high success rate in eliminating not only the human papiloma virus (HPV), but also precancerous lesions of the cervix.

            Lead Product(s): Hyaluronic Acid,Coriolus Versicolor

            Therapeutic Area: Infections and Infectious Diseases Product Name: Papilocare

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biovaxys

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement December 19, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY